Mesoblast Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Public

  • Employees
  • 108

Employees

  • Stock Symbol
  • MSB

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $1.14
  • (As of Thursday Closing)

Mesoblast General Information

Description

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 55 Collins Street
  • Level 38
  • Melbourne, Victoria 3000
  • Australia
+61 (03)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
ASX
Corporate Office
  • 55 Collins Street
  • Level 38
  • Melbourne, Victoria 3000
  • Australia
+61 (03)

Mesoblast Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mesoblast Stock Performance

As of 19-Nov-2026, Mesoblast’s stock price is $1.14. Its current market cap is $1.49B with 1.3B shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.14 $1.19 $1.13 - $2.22 $1.49B 1.3B 3.2M

Mesoblast Financials Summary

As of 30-Sep-2026, Mesoblast has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 1,995,991 1,745,106 1,465,805 795,155
Revenue 120,250 17,198 5,902
EBITDA (34,803) (79,676) (65,138)
Net Income (57,500) (102,142) (87,956)
Total Assets 773,079 784,683 669,153
Total Debt 127,334 128,157 118,923
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Mesoblast Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Mesoblast‘s full profile, request access.

Request a free trial

Mesoblast Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-
Drug Discovery
Melbourne, Australia
108 As of 2026

Sunnyvale, CA
 

Burlington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mesoblast Competitors (37)

One of Mesoblast’s 37 competitors is BioCardia, a Formerly VC-backed company based in Sunnyvale, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioCardia Formerly VC-backed Sunnyvale, CA
Minerva Neurosciences Formerly VC-backed Burlington, MA
Orbsen Therapeutics Formerly PE-Backed Galway, Ireland
Baliopharm Venture Capital-Backed Basel, Switzerland
Capricor Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 37 competitors. Get the full list »

Mesoblast Patents

Mesoblast Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2022065132-A How to treat or prevent respiratory illness Active 12-Dec-2012
JP-2020097618-A Methods for treating or preventing respiratory conditions Pending 12-Dec-2012
JP-2024041904-A Methods for treating or preventing respiratory conditions Pending 12-Dec-2012
AU-2013360026-A1 Methods of treating or preventing respiratory conditions Active 12-Dec-2012
AU-2013360026-B2 Methods of treating or preventing respiratory conditions Active 12-Dec-2012 A61K35/28
To view Mesoblast’s complete patent history, request access »

Mesoblast Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mesoblast Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Mesoblast‘s full profile, request access.

Request a free trial

Mesoblast Investments & Acquisitions (4)

Mesoblast’s most recent deal was a Merger/Acquisition with Provasculon. The deal was made on 20-Dec-2013.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Provasculon 20-Dec-2013 Merger/Acquisition Drug Discovery
Osiris Therapeutics (Culture Expanded Mesenchymal Stem Cell Business) 11-Oct-2013 Merger/Acquisition Buildings and Property
Angioblast Systems 23-Dec-2010 Merger/Acquisition Biotechnology
Angioblast Systems 20-Jan-2009 Corporate Biotechnology
To view Mesoblast’s complete investments and acquisitions history, request access »

Mesoblast ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.59 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Mesoblast’s complete esg history, request access »

Mesoblast FAQs

  • When was Mesoblast founded?

    Mesoblast was founded in 2004.

  • Where is Mesoblast headquartered?

    Mesoblast is headquartered in Melbourne, Australia.

  • What is the size of Mesoblast?

    Mesoblast has 108 total employees.

  • What industry is Mesoblast in?

    Mesoblast’s primary industry is Drug Discovery.

  • Is Mesoblast a private or public company?

    Mesoblast is a Public company.

  • What is Mesoblast’s stock symbol?

    The ticker symbol for Mesoblast is MSB.

  • What is the current stock price of Mesoblast?

    As of 19-Nov-2026 the stock price of Mesoblast is $1.14.

  • What is the current market cap of Mesoblast?

    The current market capitalization of Mesoblast is $1.49B.

  • Who are Mesoblast’s competitors?

    BioCardia, Minerva Neurosciences, Orbsen Therapeutics, Baliopharm, and Capricor Therapeutics are some of the 37 competitors of Mesoblast.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process